C4 Therapeutics Stock Discussion

$C4 Therapeutics (CCCC.US)$
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
Positive
36% overall response rate and 45% clinical benefit rate achieved in MM at highest dose level
38% overall response rate in NHL across all subtypes
44% overall response rate in PTCL specifically
No treatment emergent adverse events leading to dose reduction
Well-tolerated safety profile...

$C4 Therapeutics (CCCC.US)$
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
C4 Therapeutics (CCCC) presented Phase 1 trial data for cemsidomide at the ASH Annual Meeting, showing promising results in both multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL). In MM, cemsidomide with dexamethasone achieved a 36% overall response rate and 45% clinical b...

$C4 Therapeutics (CCCC.US)$ In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Responses Seen Across All Dose Levels
Multiple Myeloma Arm Demonstrated Well-Tolerated Safety Profile; On-Target Neutropenia Was Manageable With Low Rates of Febrile Neutropenia and Infections; No Treatment Emergent Adverse Events Le...

$C4 Therapeutics (CCCC.US)$
C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024
C4 Therapeutics (Nasdaq: CCCC) announced the release of an abstract containing clinical data from its ongoing Phase 1 trial of CFT1946, a novel BiDAC™ degrader, for mutant BRAF V600 solid tumors.
The abstract, with a data cut-off of April 12, 2024, is available on the ESMO Congress 2024 website. An oral presentation sch...

$C4 Therapeutics (CCCC.US)$
C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024
C4 Therapeutics (Nasdaq: CCCC) has announced that preliminary data from the monotherapy dose escalation portion of their ongoing Phase 1/2 clinical trial of CFT1946 will be presented at the ESMO Congress 2024 in Barcelona, Spain. CFT1946 is a novel BiDAC™ degrader targeting mutant BRAF V600 solid tumors. The present...

$C4 Therapeutics (CCCC.US)$
NEWS
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics announced an inducement grant to a new employee under Nasdaq Listing Rule 5635(c)(4). The grant includes non-qualified stock options to purchase 146,880 shares of common stock, with the options vesting over a four-year period. This grant was approved by the Company's Board of Directors and serves as an inducement for the employee to join C4 Therapeutics.

$C4 Therapeutics (CCCC.US)$ doesnt look like its gonna go up by much ..

$C4 Therapeutics (CCCC.US)$ C4 Therapeutics Has Entered Into A License Agreement With Merck KGaA, To Exclusively Discover Two Targeted Protein Degraders Against Critical Oncogenic Proteins, C4 Therapeutics Will Receive $16M As Upfront And Is Eligible Of Up $740M In Milestone Payment